Spark Therapeutics Inc (NASDAQ:ONCE) Expected to Post Quarterly Sales of $25.39 Million

Wall Street analysts predict that Spark Therapeutics Inc (NASDAQ:ONCE) will report $25.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Spark Therapeutics’ earnings, with the highest sales estimate coming in at $32.97 million and the lowest estimate coming in at $17.80 million. Spark Therapeutics reported sales of $10.71 million in the same quarter last year, which indicates a positive year-over-year growth rate of 137.1%. The business is expected to report its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $106.47 million for the current fiscal year, with estimates ranging from $72.80 million to $125.90 million. For the next year, analysts forecast that the company will report sales of $139.14 million, with estimates ranging from $137.00 million to $141.27 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.58). Spark Therapeutics had a negative return on equity of 48.70% and a negative net margin of 397.68%. The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $27.71 million.

Several analysts have commented on ONCE shares. Zacks Investment Research cut Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. Mizuho restated a “hold” rating and issued a $114.50 price target on shares of Spark Therapeutics in a report on Monday, August 12th. Finally, ValuEngine cut Spark Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $92.63.

Spark Therapeutics stock traded up $0.36 during midday trading on Thursday, reaching $109.00. The company’s stock had a trading volume of 1,963,100 shares, compared to its average volume of 568,244. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.22 and a current ratio of 5.56. The firm has a market capitalization of $4.18 billion, a PE ratio of -51.66 and a beta of 2.07. The stock’s 50 day simple moving average is $100.34 and its 200 day simple moving average is $103.10. Spark Therapeutics has a fifty-two week low of $34.53 and a fifty-two week high of $114.20.

A number of institutional investors and hedge funds have recently bought and sold shares of ONCE. CSat Investment Advisory L.P. purchased a new stake in Spark Therapeutics in the 2nd quarter valued at about $113,000. Nisa Investment Advisors LLC lifted its stake in shares of Spark Therapeutics by 651.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,010 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Spark Therapeutics in the 2nd quarter valued at about $202,000. Ancora Advisors LLC acquired a new position in shares of Spark Therapeutics in the 2nd quarter valued at about $205,000. Finally, Prudential Financial Inc. lifted its stake in shares of Spark Therapeutics by 11.7% in the 2nd quarter. Prudential Financial Inc. now owns 3,430 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 358 shares in the last quarter. Institutional investors own 86.41% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Story: Understanding Market Liquidity

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.